tbuckley/cabot-search huggingface dataset:
Atrial Fibrillation Ablation
Authors: Rakesh Latchamsetty, Fred Morady
Journal: Annual Review of Medicine (2017)

The prevalence of atrial fibrillation (AF) has risen significantly over the past two decades. Catheter ablation is an increasingly utilized treatment strategy and has evolved significantly over the same time period. Successful ablation improves patient symptoms, reduces stroke risk, and can preserve or improve cardiac function. Recurrences following ablation can occur, particularly in patients with persistent AF. Procedural efficacy can best be improved through continued advancements in ablation technology and strategy, better understanding of the mechanisms of AF initiation and perpetuation, and rigorous integration of ablation into a multidisciplinary AF management approach.
An Adolescent and Early Adulthood Dietary Pattern Associated with Inflammation and the Incidence of Breast Cancer
Authors: Holly R. Harris, Walter C. Willett, Rita L. Vaidya, Karin B. Michels
Journal: Cancer Research (2017)

Abstract Adolescence is a highly susceptible period for mammary carcinogenesis, but few prospective studies have examined the role of adolescent diet in breast cancer risk. Reduced rank regression has previously been used to identify a dietary pattern associated with markers of inflammation (C-reactive protein, IL6, and TNFα receptor 2). We investigated whether an adolescent and early adulthood inflammatory dietary pattern was associated with breast cancer among 45,204 women in the Nurses' Health Study II using reduced rank regression. Participants completed a food frequency questionnaire in 1998 about their high school diet (HS-FFQ) and a FFQ in 1991 when they were ages 27–44 years. Among women who completed the HS-FFQ, 1,477 cases of breast cancer were diagnosed during 22 years of follow-up. An adolescent and early adulthood dietary pattern characterized by inflammation was associated with an increased incidence of premenopausal but not postmenopausal breast cancer. Women in the fifth quintile of the inflammatory pattern score had multivariable adjusted HRs for premenopausal breast cancer of 1.35 for adolescent diet [95% confidence interval (95% CI), 1.06–1.73; Ptrend = 0.002] and 1.41 for early adulthood diet (95% CI, 1.11–1.78; Ptrend = 0.006) compared with women in the first quintile. The corresponding RRs for postmenopausal breast cancer were 0.84 (95% CI, 0.60–1.17) for adolescent and 0.76 (95% CI, 0.54–1.06) for adult intake. Overall, our findings support the notion that an adolescent and early adulthood diet characterized by high intake of sugar-sweetened and diet soft drinks, refined grains, red and processed meat, and margarine, and low intake of green leafy vegetables, cruciferous vegetables, and coffee may increase the incidence of premenopausal breast cancer. Cancer Res; 77(5); 1179–87. ©2017 AACR.
Activating Mutation of Heme Oxygenase (HO)-1: A Novel Disease Entity Characterized by Microcytic, Hemolytic Anemia, a Defect of Bilirubin Synthesis and Hereditary Hemophagocytic Lymphohistiocytosis.
Authors: Johann Greil, Mavi Verga-Falzacappa, Hirokazu Tsukahara, Wolfgang Behnisch, Hermann Heimpel, Marion Schneider, Gritta Janka, Maren Claus, Martina Muckenthaler, Andreas E. Kulozik
Journal: Blood (2007)
Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study
Authors: Jonathan J Keats, Gil Speyer, Austin Christofferson, Christophe Legendre, Jessica Aldrich, Megan Russell, Lori Cuyugan, Jonathan Adkins, Alex Blanski, Meghan Hodges, Dan Rohrer, Sundar Jagannath, Ravi Vij, Gregory Orloff, Todd Zimmerman, Ruben Niesvizky, Darla Liles, Joseph W. Fay, Jeffrey L. Wolf, Robert M Rifkin, Norma C Gutierrez, Mmrf CoMMpass Network, Jennifer Yesil, Mary Derome, Seungchan Kim, Winnie Liang, Pamela G. Kidd, Scott Jewell, John David Carpten, Daniel Auclair, Sagar Lonial
Journal: Blood (2016)
Albumin as a prognostic factor for overall survival in newly diagnosed patients with acute myeloid leukemia (AML).
Authors: Awais M. Khan, Jeffrey E. Lancet, Mohamed A. Kharfan-Dabaja, Najla Al Ali, Alan F. List, Rami S. Komrokji
Journal: Journal of Clinical Oncology (2012)

6586 Background: Hypoalbuminemia (HA) is an adverse prognostic factor in multiple neoplastic diseases. Severe hypoalbuminemia (&lt;3.0 g/dl) at day +90 post allogeneic hematopoietic cell transplant (AHCT) was reported as an independent predictive variable for non-relapse mortality and overall survival (Kharfan-Dabaja, et al Biol Blood Marrow Transplant 2009; 15). We examined the prognostic value of serum albumin level prior to induction chemotherapy in patients with newly diagnosed AML. Methods: Data were collected retrospectively in newly diagnosed AML patients receiving induction chemotherapy (3+ 7 regimen). Primary objective was to examine the relationship between serum albumin at baseline and probability of achieving complete remission (CR) or incomplete remission (CRi) and overall survival (OS). The Kaplan–Meier method used to estimate median overall survival; chi-square test used for comparison of categorical variables and t-test for continuous variables. Log rank test used to compare Kaplan–Meier survival estimates between two groups. Results: Between November 2004 to July 2007, 135 patients who received 3+7 induction chemotherapy were included. Patient baseline characteristics were similar between patients with serum albumin &lt; 3.5 g/dl (HA) and those with serum albumin ≥ 3.5 g/dl (no HA) with respect to age, sex, FAB subtype, history of antecedent MDS, karyotype, and chemotherapy . In patients with HA, mean age was 60 years compared to 56.5 years in non HA group. The median OS for patients with HA was 221 days (95%CI 149.5-292.5) compared to 421 days (95%CI 236.7-605) with normal serum albumin (p&lt;0.005). (Figure-1) The CR/CRi rate was 64%% for HA and 77.6% for those with normal albumin (p=0.09). In a multivariable Cox regression analysis including age ≥ 60 years, history of MDS, karyotype, and serum albumin level at baseline; only age, karyotype and serum albumin were independent predictors of OS [Hazard ratio 0.47 (95%CI 0.31-0.71) (p&lt;0.005) for normal serum albumin group]. Conclusions: In newly diagnosed AML, we demonstrate that hypoalbuminemia &lt; 3.5 g/dl is an independent covariate for overall survival with conventional chemotherapy management. The prognostic value of low serum albumin should be validated in a prospective study.
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells
Authors: Deepika Sharma Das, Abhishek Das, Arghya Ray, Yan Song, Mehmet Kemal Samur, Nikhil C. Munshi, Dharminder Chauhan, Kenneth C. Anderson
Journal: Clinical Cancer Research (2017)

Abstract Purpose: The ubiquitin proteasome pathway is a validated therapeutic target in multiple myeloma. Deubiquitylating enzyme USP1 participates in DNA damage response and cellular differentiation pathways. To date, the role of USP1 in multiple myeloma biology is not defined. In the present study, we investigated the functional significance of USP1 in multiple myeloma using genetic and biochemical approaches. Experimental Design: To investigate the role of USP1 in myeloma, we utilized USP1 inhibitor SJB3-019A (SJB) for studies in myeloma cell lines and patient multiple myeloma cells. Results: USP1-siRNA knockdown decreases multiple myeloma cell viability. USP1 inhibitor SJB selectively blocks USP1 enzymatic activity without blocking other DUBs. SJB also decreases the viability of multiple myeloma cell lines and patient tumor cells, inhibits bone marrow plasmacytoid dendritic cell–induced multiple myeloma cell growth, and overcomes bortezomib resistance. SJB triggers apoptosis in multiple myeloma cells via activation of caspase-3, caspase-8, and caspase-9. Moreover, SJB degrades USP1 and downstream inhibitor of DNA-binding proteins as well as inhibits DNA repair via blockade of Fanconi anemia pathway and homologous recombination. SJB also downregulates multiple myeloma stem cell renewal/survival-associated proteins Notch-1, Notch-2, SOX-4, and SOX-2. Moreover, SJB induced generation of more mature and differentiated plasma cells. Combination of SJB and HDACi ACY-1215, bortezomib, lenalidomide, or pomalidomide triggers synergistic cytotoxicity. Conclusions: Our preclinical studies provide the framework for clinical evaluation of USP1 inhibitors, alone or in combination, as a potential novel multiple myeloma therapy. Clin Cancer Res; 23(15); 4280–9. ©2017 AACR.
First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results
Authors: Martine Bagot, Pierluigi Porcu, Caroline Ram-Wolff, Michael Khodadoust, Maxime Battistella, Anne Marie-Cardine, Steve Mathieu, Maarten H. Vermeer, Sean Whittaker, Madeleine Duvic, Armand Bensussan, Carine Paturel, Cecile Bonnafous, Nicolas Thonnart, Agnes Widemann, Cecile Bonin, Helene Sicard, Christine Paiva, Korinna Pilz, Youn Kim
Journal: Blood (2016)
All-trans-Retinoic acid (ATRA) and Arsenic Trioxide-Induced Expression and Regulation of Programmed Cell Death 4 (PDCD4) in Acute Promyelocytic Leukemia.
Authors: Bulent Ozpolat, Maribel Tirado-Gomez, Nancy H. Colburn, Gabriel Lopez-Berestein
Journal: Blood (2004)
Association of hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ with UGT1A1 polymorphisms.
Authors: Toby Johnson, Chun-fang Xu, Toni K. Choueiri, Keith C. Deen, Zhengyu Xue, Arundathy N. Bartlett-Pandite, Christopher Carpenter, Robert John Motzer
Journal: Journal of Clinical Oncology (2013)

4569 Background: A phase III randomized clinical trial (COMPARZ) comparing pazopanib vs sunitinib for treatment of advanced renal cell carcinoma demonstrated similar efficacies but different safety profiles for the two therapies. Elevations in serum total bilirubin have been observed in patients receiving either therapy. UGT1A1 polymorphisms are associated with elevated bilirubin in the general population (Gilbert’s syndrome). This study investigated the association between functional UGT1A1 polymorphisms and on-therapy serum total bilirubin in the COMPARZ study. Methods: Patients homozygous or compound heterozygous for UGT1A1 *28, *37, and *6 alleles were predicted to have reduced UGT1A1 function. Logistic regression adjusted for ancestry principal components was used to compare patients with on-therapy hyperbilirubinemia (≥1.5 × upper limit of normal [ULN]; pazopanib, N = 62; sunitinib, N = 34) against patients exposed to treatment and with maximum on-therapy bilirubin ≤1 × ULN (pazopanib, N = 213; sunitinib, N = 215), excluding patients with maximum on-therapy bilirubin between 1 and 1.5 × ULN (pazopanib, N = 96; sunitinib, N = 104). Results: Patients with predicted reduced UGT1A1 function had higher baseline bilirubin and also were more likely to experience hyperbilirubinemia when receiving either pazopanib (P = 6.9×10 –8 ) or sunitinib (P = 1.8×10 –3 ). After adjusting for baseline bilirubin, patients with predicted reduced UGT1A1 function remained more likely to experience hyperbilirubinemia when receiving pazopanib (P = 0.015) or sunitinib (P = 0.026), with odds ratio (95% CI) 3.53 (1.28–9.76) and 4.41 (1.23–15.75), respectively. Conclusions: The data suggest that some instances of hyperbilirubinemia in patients treated with pazopanib or sunitinib may be benign manifestations of Gilbert’s syndrome. Bilirubin fractionation or, if not available, UGT1A1 genotyping, would enable further characterization of liver safety risk and help in making treatment decisions.
AMD3100 with G-CSF for Autologous Peripheral Blood Progenitor Cell (PBPC) Mobilization in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM): Mobilization, Engraftment, and Pharmacokinetics (PK).
Authors: Stewart Douglas, Clayton Smith, Ron McFarland, Karin Badel, Gary Calandra
Journal: Blood (2006)
Outpatient Busulfan (BU)/Cytoxan (CY)/VP-16 and Autologous Stem Cell Transplant (ASCT) for Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD): Comprehensive Supportive Care Program Associated with Low Treatment Related Mortality and Hospital Utilization.
Authors: Scott R. Solomon, Karen Manion, Kathy McNatt, Lawrence E. Morris, Asad Bashey, H. Kent Holland
Journal: Blood (2007)
Predicting Cerdulatinib Therapeutic Concentrations in Patients with Relapsed/Refractory B Cell Malignancies Using Preclinical Models and Clinical PK/PD and Tumor Response Correlates
Authors: Greg P. Coffey, Jiajia Feng, Glenn Michelson, Janet Leads, John T. Curnutte, Anjali Pandey, Pamela B. Conley
Journal: Blood (2015)
Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease
Authors: Jacqueline J. Eastman, Kellen J. Cavagnero, Adam S. Deconde, Alex S. Kim, Maya R. Karta, David H. Broide, Bruce L. Zuraw, Andrew A. White, Sandra C. Christiansen, Taylor A. Doherty
Journal: Journal of Allergy and Clinical Immunology (2017)
Erratum: Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis (American Journal of Respiratory and Critical Care Medicine (1995) 151 (758-767))
Authors: A. K. Sabharwal, S. P. Bajaj, A. Ameri, S. M. Tricomi, T. M. Hyers, T. E. Dahms, F. B. Taylor, M. S. Bajaj
Journal: American Journal of Respiratory and Critical Care Medicine (1995)
Abstract A48: Computational modeling of vessel growth and blood flow in the tumor microvasculature
Authors: Tae-Rin Lee, Sung Sic Yoo, Junhong Jo, Anna Go, Hyung-Kwon Seo
Journal: Cancer Research (2017)

Abstract Tumor-induced angiogenesis is important to understand the mechanism of tumor growth. However, due to its heterogeneous microenvironment, it is challenging to elucidate the correlation between tumor growth and angiogenesis. In this talk, we develop a computational model of tumor-induced angiogenesis with blood flow. The complex steps of angiogenesis are expressed by mathematical models from diffusion of growth factor, sprouting from existing vessels, vessel growth and anastomosis. Furthermore, the blood flow in the new vessels is simulated by using one dimensional flow model with hematocrit redistribution. First of all, the computational model will be validated by comparing with experimental data. In addition, the developed model will be tested in predicting tumor-induced angiogenesis with different model parameters. Finally, the future perspectives of computational modeling in tumor-induced angiogenesis will be fully discussed. Note: This abstract was not presented at the conference. Citation Format: Tae-Rin Lee, Sung Sic Yoo, Junhong Jo, Anna Go, Hyung-Kwon Seo. Computational modeling of vessel growth and blood flow in the tumor microvasculature. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr A48.
High Dose Chemotherapy Using Beam without Autologous Rescue Followed by Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Refractory or Relapsing Lymphomas - A Comparison of Delayed Versus Immediate Transplantation.
Authors: Andreas S. Buser, Martin Stern, Christoph Bucher, Caroline Arber, Dominik Heim, Joerg Halter, Sandrine Meyer-Monard, Georg Stussi, Andreas Lohri, Michele Ghielmini, Andre Tichelli, Jakob R. Passweg, Alois Gratwohl
Journal: Blood (2006)
Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α.
Authors: Carlo Gambacorti, Moshe Talpaz, Charles L. Sawyers, Brian J. Druker, Andreas Hochhaus, Charles A. Schiffer, Francois Guilhot, Dietger W. Niederwieser, Richard M. Stone, John M. Goldman, Manisha Mone, Tillmann Krahnke, Insa Gathmann, Hagop M. Kantarjian
Journal: Blood (2005)
AMD3100-Mobilized CD34+ Cells Are Phenotypically Different and Better Targets for Retroviral Transduction Than G-CSF-Mobilized CD34+ Cells in Rhesus Macaques.
Authors: Andre Larochelle, Allen Krouse, Donald Orlic, Robert E. Donahue, Cynthia E. Dunbar, Peiman Hematti
Journal: Blood (2004)
PP55. ONCOGENIC MICRORNAS REVEAL NOVEL NEURAL TUMOR MODEL
Authors: Ms Chiara Pirillo, Ms Lucia Pigazzini, Ms Elizabeth Cohen, Dr Rita Sousa-Nunes
Journal: Neuro-Oncology (2017)

Primary brain tumours are greatly diverse and are classified according to histological features, anatomical location, childhood versus adult onset, plus in a few cases genetic and epigenetic modifications. The outcome of (epi)genetic perturbations can depend on cellular context so it is relevant to enquire about the cell of origin of the various tumour types. Glioma, the most prevalent class of primary brain tumours, can originate not only from various types of glial cells but also neural stem or progenitor cells and even neurons. These cell types exist in the simple model organism Drosophila melanogaster which, along with its powerful genetics, make it a valuable model to study early steps in brain tumour formation. The small size, developmental speed, genome compaction, genetic amenability, and stereotypical and recognizeable neural lineages of the fruitfly allow for precise identification of the cell type of origin of neural tumours and mechanisms of early progression in the context of a whole organism. We have identified a number of microRNAs that are oncogenic in the context of Drosophila neural lineages. For some we have identified the tumour cell of origin as neurons and molecular characteristics of the ectopic progenitors generated using cell-type markers. We report the identification of neuron-derived fate-ambivalent progenitors.
The C-Terminal Region of the G-CSF Receptor Is Required for Induction of Neutrophil Elastase Expression in Myeloid Cells: Implication for Understanding CSF3R Mutations in Acute Myeloid Leukemia Evolving from Severe Congenital Neutropenia.
Authors: Fan Dong, Yaling Qiu, Alan D. Friedman, Qingquan Liu
Journal: Blood (2006)
Combination immunochemotherapy followed by reduced dose (rd) whole brain radiation therapy (WBRT) in an expanded cohort of patients with newly diagnosed primary central nervous system lymphoma (PCNSL)
Authors: L. E. Abrey, D. Correa, J. Yahalom, J. Raizer, S. Grimm, R. Lai, D. Schiff, B. Grant, L. M. DeAngelis, P. G. Morris
Journal: Journal of Clinical Oncology (2009)

2072 Background: High-dose methotrexate (M)-based chemotherapy combined with WBRT has improved survival in patients with PCNSL. However, disease recurrence and treatment-related neurotoxicity are significant problems. We conducted a prospective trial incorporating rituximab (R) and rdWBRT and previously demonstrated this was feasible. This study was extended to assess the long-term outcome of this approach in an expanded cohort. Methods: Patients were treated with R-MPV (d1 R 500mg/m2; d2 M 3.5gm/m2; vincristine 1.4mg/m2; d1–7 procarbazine 100 mg/m2/d on odd-cycles). Patients with a PR after five cycles received two additional cycles. Patients with a CR received rdWBRT (2340cGy), otherwise patients received standard WBRT (4500cGy). Patients then received two cycles of Ara-C 3gm/m2. Prospective neuropsychological evaluations were performed at baseline, before WBRT, and every 6 months thereafter. Results: From October 2002 to September 2008, 50 patients were enrolled (22 female, 28 male), median age 59.5 years (range 30–79 years). Due to neutropenia in two of the first five patients, all subsequent patients received G-CSF. 42 patients are assessable for response (4 patients died from progressive disease prior to completing the first cycle of treatment, 4 patients - treatment ongoing). 33 patients (79%) had a CR, of whom 29 received rdWBRT (3 refused, 1 died). At median follow-up of 3 years for survivors the median OS has not been reached and the estimated 2-year OS is 68%. Patients treated with rdWBRT have a median follow up of 38 months: 21 (72%) are alive with no evidence of disease, seven (24%) relapsed, and one died of unknown causes. Eight of 21 (38%) who are alive with no evidence of disease were age 60+ at diagnosis. The number of patients treated with rdWBRT alive with no evidence of disease at 3, 4, and 5 years is 12, 8, and 4 respectively. 9 patients have completed neuropsychological evaluations 24 months after rdWBRT with no significant cognitive decline detectable. Conclusions: Prolonged follow-up of an expanded cohort of patients treated with immunochemotherapy followed by rdWBRT for patients with an initial CR continues to support our initial conclusions that this approach results in excellent disease control with no observed treatment-related neurotoxicity. [Table: see text]
Quality and Safety in Health Care, Part XXV
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2017)

The General Thoracic Surgery Database of the Society of Thoracic Surgeons provides highly useful information in quality and safety in general thoracic surgery, including ratings of the surgeons and institutions participating in this type of surgery. This article discusses some of the work based on General Thoracic Surgery Database information regarding surgery for lung cancer and esophageal cancer.
Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).
Authors: Max S Topp, Gerhard Zugmaier, Nicola Goekbuget, Peter Kufer, Mariele Goebeler, Matthias Klinger, Evelyn Degenhard, Patrick A Baeuerle, Margit Schmidt, Dirk Nagorsen, Svenja Neumann, Heinz A Horst, Thorsten Raff, Andreas Viardot, Matthias Stelljes, Mathias Schmid, Oliver G. Ottmann, Thomas Burmeister, Hermann Einsele, Gert Riethmueller, Dieter Hoelzer, Ralf C Bargou
Journal: Blood (2009)
International Advanced Training Workshop: Psychosomatic Assessment
Authors: Hasse Karlsson, Kim Kronström, Hermann Nabi, Tuula Oksanen, Paula Salo, Marianna Virtanen, Sakari Suominen, Mika Kivimäki, Jussi Vahtera, H. Edmund Pigott, Gregory S. Alter, W. Huf, K. Kalcher, S. Kasper, C.P. Borges, E. Meyer, Y.A. Ferrão, F.P. Souza, M.B. Sousa, A.V. Cordioli, Daniela Frosini, Cristina Pagni, Claudio Lucetti, Paolo Del Dotto, Roberto Ceravolo, Ubaldo Bonuccelli, Michele Poletti, H.A. de Haan, E.A.G. Joosten, A.G.M. Wijdeveld, P.B. Boswinkel, J. van der Palen, C.A.J. De Jong, F. Cosci, T. Pennato, O. Bernini, C. Berrocal, Michael Linden, Kai Baumann, Barbara Lieberei, Constanze Lorenz, Max Rotter, Richard Balon, Judith Blatter-Meunier, Chantal Herren, Carmen Adornetto, Tina In-Albon, Kristen Lavallee, Silvia Schneider, Marij Zuidersma, Brett D. Thombs, Peter de Jonge, Jürgen Hoyer, Michael Höfler, Armin Hartmann, Stefanie Weber, Stephan Herpertz, Almut Zeeck, Satz Mengensatzproduktion, Druck Reinhardt Druck Basel, Druck Reinhardt Druck Basel, and the German Treatment Guideline Group for Anorexia Nervosa
Journal: Psychotherapy and Psychosomatics (2011)